Molecular imaging of ventricular remodeling
- First Online:
- Cite this article as:
- Zandbergen, H.R. & Schellings, M.W.M. J. Nucl. Cardiol. (2009) 16: 456. doi:10.1007/s12350-009-9078-9
- 234 Views
Cardiovascular diseases remain the number one cause of morbidity and mortality, both in the Western world and developing countries and in men and women alike.1 In 2005, the main cause of death in the USA due to disease of the heart alone was more than of all neoplastic disease combined. It is expected that these numbers will continue to increase in the coming decades due to escalating proportions of obesity and the aging population. In addition to cardiac disease, cerebrovascular disease, diabetes, and hypertension result in substantial morbidity and mortality. Therefore, cardiovascular diseases as a whole are killer number one in the Western world, and will most likely remain to be so due to adverse lifestyle changes, including unhealthy diets and lack of exercise.
Myocardial infarction (MI) is the number one cardiac disease and often strikes the individual unexpectedly; in 50% of cases MI is the first symptom of coronary atherosclerosis. Atherosclerosis is characterized by a chronic inflammatory response resulting in the formation of multiple plaques in the lumen of the artery. This can happen gradually as a result of progressive plaque growth or suddenly as a result of plaque rupture and, subsequently, thrombosis causing acute MI (AMI).
The improvements in treatment of AMI have resulted in better survival and a decrease in the acute complications of MI, such as acute congestive heart failure (CHF), myocardial rupture, arrhythmias, and conduction system disorders. However, with more patients surviving the initial stage of AMI, the development of late complications of AMI become a more prominent health care problem.
The development of left ventricular dilatation and loss of pump function in the years following the acute myocardial injury, induced by the formation of the scar, and the impact of the local loss of function on pressure and tensile forces in the noninfarcted left ventricle, are the subject of intense research. Many trials in this area have convincingly shown that inhibition of the renin–angiotensin system, through either ACE inhibitors and/or angiotensin receptor 1 blockers, preserve cardiac function and decrease mortality post MI.2 In addition, intervention in mineralocorticoid signaling has proven to preserve cardiac function and decrease mortality significantly.3,4 Despite these advances, still a substantial fraction, about one-third of AMI patients, will develop pump function disorders of the left ventricle in the long run. The outcome of a relatively recent biomarker known as NT-pro Brain Natriuretic Peptide (NT pro-BNP), which is released by cardiomyocytes after the occurrence of ventricular malfunction, has proven its usefulness in diagnosing heart failure.5 Nevertheless, it is hard to predict in which individual patient CHF will occur. Therefore, there is still a lot to be learned and to be gained from research in cardiac infarct healing and adverse left ventricular remodeling.
An upcoming diagnostic tool in analyzing the risk of cardiovascular disease in patients is cardiac imaging.6 The capability to visualize macroscopic cardiovascular structures and the anatomical and functional consequences of cardiac diseases in patients has made a remarkable progression in the last decades. The development of coronary angiography (CAG), echocardiography, magnetic resonance imaging (MRI), and multi-detector CT (MDCT) has improved our approach in diagnosing cardiovascular disease such as atherosclerosis or left ventricular function. However, most of these imaging technologies are able to diagnose the end stage of the disease, rather than the beginning of the disease or even pre-disease states. The next frontier in imaging will be the development of the capability to image fundamental biological or molecular changes which cause cardiovascular disease and are able to predict disease outcome at an early stage. For this purpose, imaging tools other than those mentioned above have to be developed.7
Imaging techniques, which visualize the fundamental biological characteristics resulting in cardiovascular disease, may provide the potential to predict cardiovascular catastrophe as an early diagnostic tool.8 With the introduction of molecular imaging, the opportunities to detect changes in biology of infarcted hearts and, therefore, cardiac remodeling in vivo have increased significantly in the past decade.
It can be hypothesized that the ability to visualize interstitial processes on a molecular level, which precede the geometric and functional deterioration of the left ventricle, should help to better predict the likelihood and rate of remodeling and development of HF.9 Several key biological features provide attractive targets for molecular imaging in heart failure. First, the development of imaging techniques visualizing the biological events of angiogenesis and fibrogenesis, which are considered key processes in myocardial scar formation and left ventricular remodeling, may provide attractive targets for the identification of patients at risk to develop a failing heart. The use of agents targeted to the integrin alpha v beta 3 (avB3) may offer diagnostic means to achieve this goal.
Second, apoptosis, a form of programmed cell death (PCD), has shown to play a key role in the process of gradual loss of pump function in animal models of heart failure, caused by different triggers. Therefore, imaging apoptosis may provide a means to identify hearts that are in the process of substantial cardiomyocyte loss and subsequent loss of pump function. The use of radiolabeled Annexin A5, which shows strong affinity to apoptotic cells which have externalized phosphatidyl serine, may provide an opportunity to develop such a heart failure imaging diagnostic test.
Finally, it is well known that the activation of the renin–angiotensin axis plays a pivotal role in the development of heart failure post AMI. Therefore, imaging of the different components of renin–angiotensin neurohumoral axis may give an additional diagnostic tool for better identification of patients prone to develop heart failure. This brief review will discuss the recent progresses made in molecular cardiac imaging, focusing mainly on the achievements made in avB3 imaging, apoptosis imaging, and imaging of the activation of the renin–angiotensin system.
avB3 Imaging as a Tool to Identify Post MI Remodeling
As described above, early diagnosis of the impact of the infarct on adverse left ventricular remodeling in the individual patient could prevent worsening of left ventricular pump function by adapting treatment to the individual needs and risks. Two main events that occur in the infarcted area are angiogenesis and collagen deposition. The formation of new blood vessels is crucial for infarct healing, and is induced by several factors, such as basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF).10 Among other regulators of angiogenesis, the avB3 integrin has been identified as a critical angiogenic modulator. Angiogenic vessels display increased expression of this critical integrin.11 This discovery led to the development of imaging tools to detect tumor angiogenesis with the use of avB3 integrin targeting agents.12,13
Recently, 18F-Galacto-RGD, a PET tracer targeting specifically avB3 integrin expression, has been introduced.15 Higuchi et al used this tracer to monitor avB3 integrin expression in rat hearts after ischemia/reperfusion, and reported results comparable with 111In-RP748 imaging.16 Clinical use of the 18F-Galacto-RGD PET tracer in a patient with MI was reported shortly.17
In conclusion, imaging of avB3 integrin has the potential to identify HF-prone patients early after MI, and thereby will help to optimize medical treatment. However, prospective clinical trials are needed to investigate whether the potential of integrin imaging translate into clinically useful diagnostic tests.
Apoptosis as a Target for Molecular Imaging in CHF
Apoptosis plays a key role in the process of degradation of cardiomyocytes resulting in ventricular dysfunction.21-24 Research in animal models of CHF has demonstrated that interference in apoptosis pathways delays the ongoing process of pump function disorders resulting in heart failure.25
One of the main biochemical characteristics of apoptosis is caspase 3 activation. The process of activation of caspase 3, an apoptosis-related cysteine protease, begins with the release of cytochrome C into the cytoplasmic area, mainly caused by oxidative stress and cytokinemia. Caspases have numerous substrates, including contractile proteins, such as troponin-T. In addition, in most cells, caspase activation results in activation of DNA fragmentation enzymes. However, it is thought that the activation of DNA fragmentation enzymes in heart muscle cells is compensated for by different antiapoptotic pathways. The consequence of apoptosis activation in cardiomyocytes is that these cells become dysfunctional, but still survive due to the preservation of DNA. This means that restoration of a healthy environment could potentially restore individual cardiomyocyte function. Another consequence of caspase 3 activation is that it results in alterations in phospholipid distribution in the sarcolemmal lipid bilayer, causing revelation of phosphatidyl serine (PS) to the surface of the cell membrane.26,27 Theoretically, the extent of PS externalization reveals an indication of the degree of apoptosis in the heart. Accordingly, it is plausible that PS can be a used as a target to detect activated cell death in heart failure. The detection of PS exposure has been proven extensively by radionuclide imaging using 99mTc-labeled Annexin A5.28,29
The AT-1 Receptor as a Target for Molecular Imaging in CHF
The essential role of the renin–angiotensin system in ventricular remodeling following AMI has been established in many experimental and clinical studies. Rather than circulating renin–angiotensin levels, it believed that myocardial upregulation of angiotensin converting enzyme, angiotensin II, and its receptors determine the likelihood of ventricular remodeling.31,32 In an experimental study in mice, it was shown that transgenic mice with deficient angiotensin II type 1 receptor expression revealed negligible remodeling post MI. Moreover, a lower expression of fibrosis and transforming growth factor (TGF-B1) was demonstrated.31 These insights from experimental models have been translated to clinical studies showing that patients with CHF patients using angiotensin receptor blockers33,34 and/or ACE-inhibitors35-37 have substantially improved survival. It has been suggested that maximization of antiangiotensin therapy, including increase in ACE-inhibitor dose or addition of ARB over ACE-inhibitor therapy, could further reduce morbidity33,38 and mortality39 in HF. It is, therefore, imaginable that accurate assessment of myocardial angiotensin receptor expression could potentially guide optimization of antiangiotensin therapy. Nowadays, diagnostic imaging of HF is focused on geometric and structural cardiac imaging.40,41
At time point of 12 weeks, the uptake was markedly reduced. Immunohistochemical analysis and 2-photon microscopy showed co-localization of the tracer with both myofibroblasts and collagen. No uptake of the fluorescent tracer was observed in cardiomyocytes. Upregulation of the AT1 receptor on myofibroblasts allows for growth factor (such as angiotensin-II)-induced proliferation and collagen production, which is believed to contribute to healing and the remodeling process following MI.43,44
Furthermore, the data showed that upregulation of angiotensin receptor preceded the development of left ventricular remodeling, as detected by echocardiography. Currently, significant emphasis is being placed on the recognition of stage A and B HF patients as a strategy of prevention of more advanced HF.45 Accordingly, development of a technology that predicts occurrence of cardiac remodeling, such as AT-1 receptor imaging, is of crucial importance, especially since the clinical practice nowadays allows diagnosis of HF only after the left ventricle has undergone adverse remodeling.
This concept is further emphasized by the recent demonstration of another strategy for imaging renin–angiotensin axis with the use of radiolabeled benzoyl lisinopril. Dilsizian et al incubated short-axis myocardial slices explanted from patients undergoing cardiac transplantation for end-stage ischemic cardiomyopathy with F-18 fluoro-benzoyl lisinopril.46 There was specific binding of radiotracer to ACE; mean binding was 6.6 ± 5.2 compared with 3.4 ± 2.5 luminescence/mm2 in segments pre-incubated with cold lisinopril (P < 0.0001). Furthermore, mean radiotracer binding was 6.3 ± 4.5 in infarcted, 7.6 ± 4.7 in peri-infarcted, and 5.0 ± 1.0 luminescence/mm2 remote noninfarcted (P < 0.02) segments. Together, these imaging studies demonstrate that activation of the renin–angiotensin system can be visualized using molecular imaging technology. Both studies also showed that the components of the tissue renin–angiotensin cascade are upregulated only about 2- to 3-fold. It remains unclear whether such relatively small difference between remodeling cardiac tissue and control hearts could provide a clinically robust diagnostic strategy for imaging targeted to ATR and/or ACE.
Based on the preclinical and clinical data obtained in molecular imaging of adverse left ventricular remodeling, the current outlook for the development of such an imaging technology is promising. For both the imaging of avB3 integrin and imaging of phosphatidyl serine expression as a reflection of caspase 3 activation, the preliminary data provide a sufficient basis for the design and execution of novel studies. For imaging of the components of the renin–angiotensin system, the extent of uptake may be insufficient to form a basis for clinical applications. However, before one of these technologies could be adopted as diagnostic tests for routine clinical use, large clinical studies need to be conducted to address key questions. For instance, it is still unknown whether the uptake of avB3 targeting tracers is robust enough to uncover patients that are at the brink of developing adverse remodeling post MI. In addition, it remains to be seen whether the extent of the uptake of the tracer can be modulated by treatment with different regimes of CHF treating compounds. Studies focused on addressing these questions are under way.
For imaging phosphatidyl serine exposure in the heart using Annexin A5, as a reflection of caspase-3 activation, the outlook depends largely on the availability of clinically graded Annexin A5 imaging diagnostic kits. With the availability of clinical Annexin A5 imaging kits, studies could be designed to further explore the predictive value of Annexin A5 in patients with failing hearts and to study the effect of therapeutic interventions.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.